{
  "clinical_study": {
    "title": "A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension",
    "nct_identifier": "NCT06137742",
    "indication": "Pulmonary Arterial Hypertension",
    "intervention": "PF-07868489, Placebo for PF-07868489",
    "study_arms": {
      "intervention": 1,
      "placebo": 1
    },
    "number_of_participants": 90,
    "average_age": null,
    "age_range": [
      "18 Years",
      "65 Years"
    ],
    "interventional_drug": [
      {
        "name": "PF-07868489",
        "dose": null,
        "frequency": null,
        "formulation": null
      },
      {
        "name": "Placebo for PF-07868489",
        "dose": null,
        "frequency": null,
        "formulation": "Placebo"
      }
    ],
    "endpoints": [
      "Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)",
      "Number of Participants With Change From Baseline in Laboratory Tests Results",
      "Number of Participants With Vital Sign Abnormalities",
      "Number of Participants With Change From Baseline in Electrocardiogram (ECG) Parameters",
      "Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)",
      "Number of Participants With Change From Baseline in Laboratory Tests Results",
      "Number of Participants With Vital Sign Abnormalities",
      "Number of Participants With Change From Baseline in Electrocardiogram (ECG) Parameters",
      "Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration at Week24",
      "Area Under the Plasma Concentration-time Profile From Time Zero to the Time of Last Quantifiable Concentration (AUClast)",
      "Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)",
      "Maximum Observed Plasma Concentration (Cmax)",
      "Time to Reach Maximum Observed Plasma Concentration (Tmax)",
      "Incidence of Anti-Drug Antibody (ADA)",
      "Plasma Decay Half-Life (t1/2)",
      "Minimum Observed Plasma Trough Concentration (Cmin)",
      "Plasma Decay Half-Life (t1/2)",
      "Incidence of Anti-Drug Antibody (ADA)",
      "PVR",
      "6MWD"
    ],
    "baseline_characteristics": []
  },
  "endpoints": [
    {
      "name": "Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)",
      "description": "Part A",
      "timepoint": "Baseline up to Day 113.",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Number of Participants With Change From Baseline in Laboratory Tests Results",
      "description": "Part A",
      "timepoint": "Baseline up to Day 113",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Number of Participants With Vital Sign Abnormalities",
      "description": "Part A",
      "timepoint": "Baseline up to Day 113",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Number of Participants With Change From Baseline in Electrocardiogram (ECG) Parameters",
      "description": "Part A",
      "timepoint": "Baseline up to Day 113",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)",
      "description": "Part B",
      "timepoint": "Baseline up to Day 253",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Number of Participants With Change From Baseline in Laboratory Tests Results",
      "description": "Part B",
      "timepoint": "Baseline up to Day 253",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Number of Participants With Vital Sign Abnormalities",
      "description": "Part B",
      "timepoint": "Baseline up to Day 253",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Number of Participants With Change From Baseline in Electrocardiogram (ECG) Parameters",
      "description": "Part B",
      "timepoint": "Baseline up to Day 253",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration at Week24",
      "description": "repeated doses",
      "timepoint": "Baseline, Week 24",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Area Under the Plasma Concentration-time Profile From Time Zero to the Time of Last Quantifiable Concentration (AUClast)",
      "description": "single dose",
      "timepoint": "Pre dose, 8, 12, 24, 48,72,96,168,336 hours post dose",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)",
      "description": "single dose",
      "timepoint": "Pre dose, 8, 12, 24, 48,72,96,168,336 hours post dose",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Maximum Observed Plasma Concentration (Cmax)",
      "description": "single dose",
      "timepoint": "Pre dose, 8, 12, 24, 48,72,96,168,336 hours post dose",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Time to Reach Maximum Observed Plasma Concentration (Tmax)",
      "description": "single dose",
      "timepoint": "4-7 days",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Incidence of Anti-Drug Antibody (ADA)",
      "description": "single dose",
      "timepoint": "Baseline and up to week 16",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Plasma Decay Half-Life (t1/2)",
      "description": "single dose",
      "timepoint": "Day 113",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Minimum Observed Plasma Trough Concentration (Cmin)",
      "description": "repeat doses",
      "timepoint": "Day 253",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Plasma Decay Half-Life (t1/2)",
      "description": "repeat doses",
      "timepoint": "Day 253",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "Incidence of Anti-Drug Antibody (ADA)",
      "description": "repeated doses",
      "timepoint": "Baseline and up to Day 253",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "PVR",
      "description": "repeated doses",
      "timepoint": "Baseline, Week 24",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    },
    {
      "name": "6MWD",
      "description": "repeated doses",
      "timepoint": "Baseline, Week 24",
      "arm": null,
      "average_value": null,
      "upper_end": null,
      "lower_end": null,
      "statistical_significance": null
    }
  ],
  "baseline_measures": []
}